These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24497930)

  • 1. Subclinical elevation of plasma C-reactive protein and illusions/hallucinations in subjects with Parkinson's disease: case-control study.
    Sawada H; Oeda T; Umemura A; Tomita S; Hayashi R; Kohsaka M; Yamamoto K; Sudoh S; Sugiyama H
    PLoS One; 2014; 9(1):e85886. PubMed ID: 24497930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive identification of delusions and olfactory, tactile, gustatory, and minor hallucinations in Parkinson's disease psychosis.
    Kulick CV; Montgomery KM; Nirenberg MJ
    Parkinsonism Relat Disord; 2018 Sep; 54():40-45. PubMed ID: 29653909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative.
    Ffytche DH; Pereira JB; Ballard C; Chaudhuri KR; Weintraub D; Aarsland D
    J Neurol Neurosurg Psychiatry; 2017 Apr; 88(4):325-331. PubMed ID: 28315846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics, correlates, and assessment of psychosis in Parkinson disease without dementia.
    Barrett MJ; Smolkin ME; Flanigan JL; Shah BB; Harrison MB; Sperling SA
    Parkinsonism Relat Disord; 2017 Oct; 43():56-60. PubMed ID: 28735797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline Plasma C-Reactive Protein Concentrations and Motor Prognosis in Parkinson Disease.
    Umemura A; Oeda T; Yamamoto K; Tomita S; Kohsaka M; Park K; Sugiyama H; Sawada H
    PLoS One; 2015; 10(8):e0136722. PubMed ID: 26308525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of selegiline and levodopa combination therapy versus levodopa monotherapy in the treatment of Parkinson's disease: a meta-analysis.
    Jiang DQ; Li MX; Jiang LL; Chen XB; Zhou XW
    Aging Clin Exp Res; 2020 May; 32(5):769-779. PubMed ID: 31175606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study of associated clinical variables and phenomenology of hallucinations in Parkinson's].
    Cubo E; González M; Aguilar A; Quintana S
    Neurologia; 2006; 21(1):12-8. PubMed ID: 16525921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the Spectrum of Visual Illusions and Other Minor Hallucinations in Patients with Parkinson's Disease in Lithuania.
    Jucevičiūtė N; Balnytė R; Laucius O
    Medicina (Kaunas); 2024 Apr; 60(4):. PubMed ID: 38674252
    [No Abstract]   [Full Text] [Related]  

  • 11. Prospective longitudinal assessment of hallucinations in Parkinson's disease.
    Goetz CG; Leurgans S; Pappert EJ; Raman R; Stemer AB
    Neurology; 2001 Dec; 57(11):2078-82. PubMed ID: 11739829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychosis in Parkinson's Disease: Looking Beyond Dopaminergic Treatments.
    Rojas M; Chávez-Castillo M; Duran P; Ortega Á; Bautista-Sandoval MJ; Salazar J; Riaño-Garzón M; Chacín M; Medina-Ortiz O; Palmar J; Cudris-Torres L; Bermúdez V
    Curr Pharm Des; 2022; 28(33):2725-2741. PubMed ID: 36321314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between age and subtypes of psychotic symptoms in Parkinson's disease.
    Kiziltan G; Ozekmekçi S; Ertan S; Ertan T; Erginöz E
    J Neurol; 2007 Apr; 254(4):448-52. PubMed ID: 17401525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deconstructing psychosis and misperception symptoms in Parkinson's disease.
    Nishio Y; Yokoi K; Uchiyama M; Mamiya Y; Watanabe H; Gang M; Baba T; Takeda A; Hirayama K; Mori E
    J Neurol Neurosurg Psychiatry; 2017 Sep; 88(9):722-729. PubMed ID: 28600444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visual hallucinations in photographs in Parkinson's disease.
    Vaou O; Saint-Hilaire M; Friedman J
    BMJ Case Rep; 2013 May; 2013():. PubMed ID: 23704424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Psychoses in patients with Parkinson's disease; their frequency, phenomenology, and clinical correlates].
    Kashihara K; Ohno M; Katsu Y
    Rinsho Shinkeigaku; 2005 Jan; 45(1):1-5. PubMed ID: 15714992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and evaluation of the Parkinson Psychosis Questionnaire A screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson's disease.
    Brandstaedter D; Spieker S; Ulm G; Siebert U; Eichhorn TE; Krieg JC; Oertel WH; Eggert K
    J Neurol; 2005 Sep; 252(9):1060-6. PubMed ID: 15789127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hallucinations and psychosis in Parkinson's disease.
    Rabey JM
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S105-10. PubMed ID: 20123547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of psychotic symptoms in a community-based Parkinson disease sample.
    Mack J; Rabins P; Anderson K; Goldstein S; Grill S; Hirsch ES; Lehmann S; Little JT; Margolis RL; Palanci J; Pontone G; Weiss H; Williams JR; Marsh L
    Am J Geriatr Psychiatry; 2012 Feb; 20(2):123-32. PubMed ID: 21617521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.